Will you be attending the 2025 @AADMember Annual Meeting in Orlando, Florida? Join us on March 8th as our Chief Scientific Officer, Dr. Chris VanDeusen, presents #ClinicalData from our lead Nck modulator’s evaluation in atopic dermatitis models. More here:

Reach out to us at info@artaxbiopharma.com to get access to the results - we'd love to hear from you. And read our press release here:

Reach out to us at info@artaxbiopharma.com to get access to the results - we'd love to hear from you. And read our press release here:

"With this validation, we are now enabled to further expand the study of our lead compound AX-158 as a daily oral therapeutic for a broad spectrum of autoimmune diseases." - Dr. Scott Batty, CMO Artax Biopharma.

"I am pleased to share with you the successful completion of our Phase 2a psoriasis study. Thanks to the patients and dedicated researchers involved, we have confirmed the role of Nck modulation as a key target for intervention in autoimmune diseases."

And read our press release here:

Artax Biopharma CEO Rob Armstrong had some words about the paradigm shifting potential of our novel mechanism for autoimmune disease treatment. Reach out to us at info@artaxbiopharma.com to get access to the results - we'd love to hear from you.

These results confirm the strong Phase 1 and preclinical data package, underscoring the potential breadth and depth of Nck modulation, a completely novel mechanism in autoimmune disease. Read the full release: #biotech #breakthrough #autoimmunedisease

Please ping Maria Nichol, CBO, to set up a meeting if you'd like to talk to us about life, science and Nck modulation.

With 2025 right around the corner, we're incredibly excited to be heading to San Francisco in January. The Artax team will be there in force, and we are looking forward to a busy schedule catching up with our biotech and pharma friends and colleagues.

While we wait for the data in psoriasis patients with our lead program AX-158, Artax CSO Dr. Christopher VanDeusen wanted to share some thoughts on what's next for AX-158.

Happy Thanksgiving from all of us at Artax Biopharma! We're thankful for the members of our team who have committed themselves to our vision in 2024 and to the patients who've participated in our clinical trials.

Our own Dr. Christopher VanDeusen, CSO of Artax, will be presenting at #ACR24 today from 10:30 AM -12:30 PM! Learn more about the promise of TCR-Nck Modulators for the treatment of autoimmune diseases.

Dr. Scott Batty, CMO of Artax, will be presenting on the tolerability and pharmacokinetics of the T cell receptor signal modulator at #ACR24 from 10:30 AM - 12:30 PM today. Come see us!

We're here at #ACR24! Come find us and chat about what Artax has coming in the next few months.

We are simultaneously developing additional Nck modulator candidates for #autoimmunediseases with AX-194 undergoing preclinical testing to enter Phase 1 trials. Learn more about our candidate pipeline here: . #clinincaltrials #immunology.

We're excited by the progress we've been making in the development of our first novel mechanism, AX-158, as we rapidly approach results from our phase 2 trials for psoriasis treatment with first results expected in December 2024.

At Artax Biopharma, we are developing first-in-class Nck modulators to treat T cell mediated autoimmune disease such as #psoriasis, #atopicdermatitis, and more.

#ACR2024 is around the corner and we're looking forward to connecting with any and all who are attending!.

Come find us at Bio Europe from November 4–6, 2024. Let's chat about the promise of Nck modulators in person.